Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response provides the most comprehensive body of knowledge available on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients. As a consequence of the intrinsic chromosomal and genetic instability of the tumor genome, it is generally believed that tailoring of chemotherapy in cancer - tients might be achieved by molecular analysis of patient tumor DNA. In addition, to reduce the toxicity risk of patients, the tumor DNA information should be in- grated with the available data on polymorphic drug-metabolizing enzyme and tra- porter genes mediating the exposure of patients to active drugs and/or their active metabolites. The chapters of this book clearly show how DNA information from both the host (germline) and the tumor should be taken into account for rational selection of drug therapies in cancer patients, an aspect that received little attention, despite its importance. The availability of new molecular approaches to the selection of drug therapy is an emerging need, because the traditional approach based on the evaluation of patient and tumor characteristics is clearly far from optimal. Many treated patients do not experience signi?cant bene?ts from the treatment, while they often experience moderate to severe toxicities. In addition, the development and clinical use of novel molecularly targeted agents (alone or in combination with classical cytotoxic therapy) requires the und- standing of the molecular features of the tumors and the identi?cation of tumor markers of response.
Comprehensive reference for researchers in the field of cancer pharmacogenomics and clinicians, from both academia and industry
Provides a collection of multi-disciplinary topics
Covers the most important aspects of pharmacogenomics applied to cancer patients
The availability of new molecular approaches to the selection of drug therapy is an emerging need, as the traditional approach based on the evaluation of patient and tumor characteristics is clearly far from optimal. Many, and in most cases the majority of treated patients do not have significant benefits from the treatment while they often experience moderate to severe toxicities. In "Pharmacogenomics, Anticancer Drug Discovery, and Response," edited by Federico Innocenti, readers will find a series of chapters addressing the role of genomic information in cancer therapy and in drug development representing a unique source, as it describes experimental approaches, statistical strategies, and clinical examples of the application of genomic medicine in oncology. This book provides the most comprehensive body of knowledge on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients.
pharmacoGENOMICS, ANTICANCER DRUG DISCOVERY, AND RESPONSE Book editor: Federico Innocenti, M.D., Ph.D. Genomic experimental approaches in oncology Toward the realisation of the promise of microarrays in oncology Neil Winegarden Cell based models to identify genetic variants contributing to anticancer drug response M. Eileen Dolan Proteomic analysis in cancer patients Kazuyuki Nakamura MicroRNAs and discovery of new targets Gozoh Tsujimoto Pharmacogenomics of the National Cancer Institute’s 60 tumor cell panel David G. Covell Use of single nucleotide polymorphism array for tumor aberrations in gene copy numbers Kwong-Kwok Wong Pharmacogenomics of toxicity and response of chemotherapy Concordance between tumor and germline DNA Sharon Marsh Epidermal growth factor receptor mutations and sensitivity to selective kinase inhibitors in human lung cancer Jeffrey Settleman 3. BCR-ABL mutations and imatinib resistance in chronic myeloid leukemia patients Mark Litzow Role of thymidylate synthase gene variations in colorectal cancer patients Heinz-Josef Lenz Thiopurines in the treatment of childhood acute lymphoblastic leukemia and genetic variants in the thiopurine S-methyltransferase gene Martin Stanulla The impact of polymorphisms on the clinical outcomes of monoclonal antibody therapy against hematologic malignancies Dong Hwan Kim DNA repair and mitotic check point genes as potential predictors of chemotherapy response in non-small-cell lung cancer Rafael Rosell Dihydropyrimidine dehydrogenase (DPYD) gene polymorphism: portrait of a serial killer. Gerard Milano Impact of UDP-glucuronosyltransferase 1A haplotypes on irinotecan treatment Kimie Sai Microarray profiling in breast cancer patients Lan Guo 11. Role of the folate pathway and the thymidylate synthase genes in pediatric acute lymphoblastic leukemia treatment response Richard Aplenc Pharmacogenomics in clinical drug development in oncology Pharmacogenomics in drug development: an pharmaceutical industry perspective Tal Zaks Identification of a pharmacogenomic biomarker classifiers in cancer drug development Richard Simon Toxicogenomics application to oncology drug development Teresa Lettieri Strategies to identify pharmacogenomic biomarkers: candidate gene, pathway-based, and genome-wide approaches Xifeng Wu